cover of episode The future of coronary arteries

The future of coronary arteries

2025/2/14
logo of podcast The Future of Everything

The Future of Everything

AI Deep Dive AI Chapters Transcript
People
K
Kristy Red-Horse
R
Russ Altman
Topics
Russ Altman: 我认为避免开胸进行四重搭桥手术会更好,特别是对于有合并症的老年人。如果可以通过药物来促进新的旁路动脉生长,那么可以在需要冠状动脉搭桥手术之前更早地进行干预。冠状动脉搭桥手术是一个大手术,需要开胸,并且经常需要体外循环,术后胸骨上会留下很大的疤痕,恢复期也很长。现在,有可能通过注射药物来刺激新动脉的生长,从而绕过阻塞并与下游动脉连接,实现自然搭桥。克里斯蒂发现了可以刺激新动脉生长的关键分子,这为冠状动脉搭桥手术提供了一个全新的未来,或许在某些或所有情况下可以消除手术,转而使用药物来促进新动脉的生长。 Kristy Red-Horse: 我认为开胸手术非常具有侵入性,是一个大型手术。如果可以通过药物来促进新的旁路动脉生长,那么可以在需要冠状动脉搭桥手术之前更早地进行干预。发现是什么让动脉生长是一个关键挑战。刺激毛细血管生长的分子与刺激大动脉生长的分子并不完全相同。像VEGF和FGF这样的分子会促进毛细血管的生长,而我们需要的是能够促进更大血管生长的分子,以便带来更多的血液流动。我们现在需要了解动脉如何特异性地生长,以便获得更大的血管,从而带来更多的血液流动,并灌注那些较小的血管。促进动脉生长的蛋白质具有多效性,需要在心脏中非常精确地靶向这些通路,以避免在全身其他地方引起不必要的生长。这些通路会刺激免疫系统,并刺激体内各种细胞类型的生长,而不仅仅是动脉。通过研究胚胎发生过程中动脉的生成方式,或许可以重复利用这些通路来再生受损或患病的心脏中的动脉。

Deep Dive

Chapters
This chapter explores the drawbacks of coronary artery bypass surgery, highlighting its invasiveness and lengthy recovery time. It introduces the concept of medically growing new arteries as a less invasive alternative, potentially applicable earlier in the disease process.
  • Open-heart surgery is invasive and requires long recovery.
  • Medically growing new arteries could be less invasive and applied earlier.
  • The goal is to avoid open-heart surgery and treat the disease earlier.

Shownotes Transcript

Guest Kristy Red-Horse) is a biologist who specializes in coronary artery development and disease. She says the latest advances in treatment of blockages could do away with invasive bypass surgeries in favor of growing new arteries using molecules like CXCL12, known to promote artery regrowth in mice. Red-Horse explains how leaps forward in medical imaging, expanding atlases of gene expressions, and new drug delivery mechanisms could someday lead to trials in humans. But, before that day can arrive, much work remains, as Red-Horse tells host Russ Altman) in this episode of Stanford Engineering’s The Future of Everything podcast.

Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to [email protected]).

Episode Reference Links:

Connect With Us:

Chapters:

(00:00:00) Introduction

Russ Altman introduces Kristy Red-Horse, a professor of biology at Stanford University.

(00:03:46) Replacing Open-Heart Surgery

Why bypass surgery is invasive, risky, and requires long recovery.

(00:05:09) Challenges in Artery Growth

The difficulty of targeting artery growth with medical interventions.

(00:07:32) The Role of Collateral Arteries

Definition and function of collateral arteries as natural bypass.

(00:09:37) Triggers for Natural Bypass Formation

Genetic factors that may influence the growth of these bypass arteries.

(00:10:49) Unique Properties of Coronary Arteries

Challenges of ensuring artificial growth replicates natural artery function.

(00:13:04) The Discovery of CXCL12

A key molecule that stimulates collateral artery formation.

(00:16:16) Precise Artery Growth Control

The results of targeted CXCL12 injections into mice hearts.

(00:17:32) CXCL12’s Overlooked Role

The molecule’s role in the immune system and stem cells.

(00:20:27) Guinea Pigs and Heart Attack Resistance

How guinea pigs naturally develop collaterals.

(00:23:19) Preventing Heart Disease

Using artery growth treatments to target early-stage coronary disease.

(00:25:25) Breakthroughs in Imaging Technology

New technology that enables identification of collateral growth pathways.

(00:27:07) How Collateral Arteries Form

The two mechanisms in which new arteries form.

(00:28:48) The Future of Medical Artery Growth

The possibility of eliminating bypass surgery with targeted artery growth.

Connect With Us:

Episode Transcripts >>> The Future of Everything Website)

Connect with Russ >>> Threads) / Bluesky) / Mastodon)

Connect with School of Engineering >>>Twitter/X) / Instagram) / LinkedIn) / Facebook)